, Décrire les toxidromes liés aux NPS et apparentés identifiés

, Décrire la fréquence des polyintoxications (plusieurs molécules identifiées)

, Décrire la mortalité des intoxications aux NPS et apparentés

, Décrire la morbidité des intoxications aux NPS et apparentés

, Décrire la prise en charge habituelle des intoxications aux NPS et apparentés. D. Critères de jugements secondaires

, Symptômes cliniques observés chez les patients intoxiqués aux NPS et apparentés

, Pourcentage de co-intoxications incluant des NPS et apparentés

, Mortalité hospitalière jusqu'à un mois exprimée en pourcentage

, Pourcentage d'admissions en réanimation jusqu'à 1 mois après l'inclusion, durée d'hospitalisation

, Description des thérapeutiques mises en oeuvre dans les 24h suivant l'admission (perfusions de solutés, médicaments et antidotes administrés, mesures réanimatoires)

. Population,

, Etude prospective, multicentrique avec recrutement consécutif sur une période d'inclusion fixe

, Utilisation d'antidote(s) naloxone ; quantité : ?????????. flumazenil ; quantité : ????????

:. Bleu-de-méthylène-;-quantité and . ?????, autre ; précisez lequel et quantité : ??? Administration d'autres médicaments paracétamol ; quantité : ???????? rivotril ; quantité : ??????????. loxapine ; quantité : ?????????.. valium ; quantité : ??????????. dobutamine, précisez posologie : ????. atropine, précisez quantité : ??????.. autre

, Mesures réanimatoires remplissage vasculaire ; précisez lequel et quantité : ??????????????? noradrénaline

|. __-|-|-__-|-|-__-|-|-__-|-|-__-|-|-__-|--|-__-|-centre-ordre, précisez médicaments utilisés et quantité : ?????. réanimation cardiopulmonaire: No-flow ?????mn Low-flow ?????mn Adrénaline ?????mg IVD dialyse Etude SkiTox Identifiant Sujet

. Document-annexe,

, Cette feuille doit être complétée pour toute sortie du patient avant le terme de l'essai. Date d'arrêt précoce : ??????????????????? jj/mm/aaaa

. .. , Cause d'arrêt précoce : retrait de consentement, date ??????????????????? jj/mm/aaaa autres, précisez : ???????????????????

E. Sujet and ;. Ordre,

. Bibliographie,

, Stupéfiants et psychotropes -ANSM : Agence nationale de sécurité du médicament et des produits de santé. Disponible sur, 1990.

E. Engidawork, Pharmacological and Toxicological Effects of Catha edulis F

, Khat Pharmacology and Toxicology. Phytother Res. juill, vol.31, issue.7, pp.1019-1047, 2017.

M. Majchrzak, R. Celi?ski, P. Ku?, T. Kowalska, and M. Sajewicz, The newest cathinone derivatives as designer drugs: an analytical and toxicological review, Forensic Toxicol. janv, vol.36, issue.1, pp.33-50, 2018.

M. J. Valente, G. De-pinho, P. De, L. Bastos, M. Carvalho et al., Khat and synthetic cathinones: a review, Arch Toxicol. janv, vol.88, issue.1, pp.15-45, 2014.

L. Simmler, T. Buser, M. Donzelli, Y. Schramm, L. Dieu et al.,

, Pharmacological characterization of designer cathinones in vitro: Pharmacology of cathinones, Br J Pharmacol. janv, vol.168, issue.2, pp.458-70, 2013.

E. Tyrkkö, M. Andersson, and R. Kronstrand, Kersten BP, McLaughlin ME. Toxicology and Management of Novel Psychoactive Drugs. Ferrell KW, Hill AM, éditeurs, J Pharm Pract. févr, vol.38, issue.2, pp.50-65, 2015.

J. B. Zawilska, Synthetic Cathinones: Novel Addictive and Stimulatory Psychoactive Substances, vol.215, 2018.

S. Zaami, R. Giorgetti, S. Pichini, F. Pantano, E. Marinelli et al., Synthetic cathinones related fatalities: an update, Eur Rev Med Pharmacol Sci. janv, vol.22, issue.1, pp.268-74, 2018.

G. Loeffler, D. Hurst, P. A. , Y. K. Spice, B. Salts et al., The Emergence of Synthetic Cannabinoid Receptor Agonists and Cathinones in the U.S. Armed Forces, Mil Med. sept, vol.177, issue.9, pp.1041-1049, 2012.

R. Graddy, M. E. Buresh, and D. A. Rastegar, New and Emerging Illicit Psychoactive Substances, Med Clin North Am. juill, vol.102, issue.4, pp.697-714, 2018.

J. B. Zawilska and D. Andrzejczak, Next generation of novel psychoactive substances on the horizon -A complex problem to face, Drug Alcohol Depend. déc, vol.157, pp.1-17, 2015.

J. V. Rivera, E. G. Vance, W. F. Rushton, and J. K. Arnold, Novel Psychoactive Substances and Trends of Abuse: Crit Care Nurs Q, vol.40, pp.374-82, 2017.

G. S. Wang and C. Hoyte, Novel Drugs of Abuse, Pediatr Rev. févr, vol.40, issue.2, pp.71-79, 2019.

B. J. Warrick, A. P. Tataru, and R. Gerona, New Psychoactive Substances in Pediatric Patients

, Pediatr Clin North Am. déc, vol.64, issue.6, pp.1223-1264, 2017.

B. K. Logan, A. Mohr, M. Friscia, A. J. Krotulski, D. M. Papsun et al.,

, A Review, Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, vol.41, pp.573-610, 2017.

M. Kraemer, A. Boehmer, B. Madea, and A. Maas, Death cases involving certain new psychoactive substances: A review of the literature, Forensic Sci Int. mai, vol.298, pp.186-267, 2019.

A. L. Riley, K. H. Nelson, P. To, R. López-arnau, P. Xu et al., Abuse potential and toxicity of the synthetic cathinones (i.e., « Bath salts »), Neurosci Biobehav Rev, vol.14, issue.2019

S. L. Hill and S. Thomas, Clinical toxicology of newer recreational drugs, Clin Toxicol, vol.49, issue.8, pp.705-724, 2011.

K. Thorlacius, C. Borna, and M. Personne, Bromo-dragon fly--life-threatening drug

, Lakartidningen. 16 avr, vol.105, issue.16, pp.1199-200, 2008.

S. Thornton, D. Lisbon, T. Lin, R. Gerona, and P. Beyond-ketamine,

, Analytically Confirmed Use of Multiple Novel Arylcyclohexylamines, J Psychoactive Drugs. 8 août, vol.49, issue.4, pp.289-93, 2017.

G. Bokor and P. D. Anderson, Ketamine: An Update on Its Abuse, J Pharm Pract. déc

K. E. Hofer, C. Degrandi, D. M. Müller, U. Zürrer-härdi, S. Wahl et al.,

, Acute toxicity associated with the recreational use of the novel dissociative psychoactive substance methoxphenidine, Clin Toxicol. déc, vol.52, issue.10, pp.1288-91, 2014.

J. Carlier, R. Giorgetti, M. R. Varì, F. Pirani, G. Ricci et al., Use of cognitive enhancers: methylphenidate and analogs, p.13

A. M. Araújo, F. Carvalho, L. Bastos-m-de, G. De-pinho, P. Carvalho et al., The hallucinogenic world of tryptamines: an updated review, Arch Toxicol. août, vol.89, issue.8, pp.1151-73, 2015.

J. Orsini, N. Din, E. Elahi, A. Gomez, S. Rajayer et al., Clinical and epidemiological characteristics of patients with acute drug intoxication admitted to ICU, J Community Hosp Intern Med Perspect, vol.7, issue.4, pp.202-209, 2017.

A. Helander, M. Bäckberg, P. Hultén, Y. Al-saffar, and O. Beck, Detection of new psychoactive substance use among emergency room patients: Results from the Swedish STRIDA project, Forensic Sci Int. oct, vol.243, pp.23-32, 2014.

R. Tittarelli, G. Mannocchi, F. Pantano, and F. S. Romolo, Recreational Use, Analysis and Toxicity of Tryptamines, Curr Neuropharmacol. janv, vol.13, issue.1, pp.26-46, 2015.

D. M. Boland, W. Andollo, G. W. Hime, and W. L. Hearn, Fatality due to acute alphamethyltryptamine intoxication, J Anal Toxicol. août, vol.29, issue.5, pp.394-401, 2005.

R. A. Morano, C. Spies, F. B. Walker, and S. M. Plank, Fatal intoxication involving etryptamine

, J Forensic Sci. mai, vol.38, issue.3, pp.721-726, 1993.

G. Alatrash, N. S. Majhail, and J. C. Pile, Rhabdomyolysis After Ingestion of "Foxy

. Hallucinogenic-tryptamine-derivative, Mayo Clin Proc. 1 avr, vol.81, issue.4, pp.550-551, 2006.

A. J. Adams, S. D. Banister, L. Irizarry, J. Trecki, M. Schwartz et al.,

, Outbreak Caused by the Synthetic Cannabinoid AMB-FUBINACA in New York, On behalf of the ACMT Toxicology Investigators Consortium (ToxIC), vol.376, pp.235-242, 2017.

D. P. Calello, R. R. Gerona, E. Hamad, and S. L. Campleman, Characteristics and Treatment of Patients with Clinical Illness Due to Synthetic Cannabinoid Inhalation Reported by Medical Toxicologists: A ToxIC Database Study, J Med Toxicol. juin, vol.13, issue.2, pp.146-52, 2017.

P. Al, Les cannabinoïdes de synthèse : épidémiologie, modalités de consommations et effets cliniques, Toxicol Anal Clin. mars, vol.27, pp.33-40, 2015.

N. Misailidi, I. Papoutsis, P. Nikolaou, A. Dona, C. Spiliopoulou et al.,

, Fentanyls continue to replace heroin in the drug arena: the cases of ocfentanil and carfentanil, Forensic Toxicol. janv, vol.36, issue.1, pp.12-32, 2018.

P. Armenian, K. T. Vo, J. Barr-walker, and K. L. Lynch, Fentanyl, fentanyl analogs and novel synthetic opioids: A comprehensive review, Neuropharmacology. mai, vol.134, pp.121-153, 2018.

L. Karila, M. Marillier, B. Chaumette, J. Billieux, N. Franchitto et al., New synthetic opioids: Part of a new addiction landscape, Neurosci Biobehav Rev, p.0149763418301143, 2018.

S. P. Elliott, H. Lopez, and E. , A Series of Deaths Involving Carfentanil in the UK and Associated Post-mortem Blood Concentrations, J Anal Toxicol. 1 mai, vol.42, issue.4, p.110, 2017.

J. Suzuki and S. El-haddad, A review: Fentanyl and non-pharmaceutical fentanyls, Drug Alcohol Depend. févr, vol.171, pp.107-123, 2017.

N. J. Somerville, J. O'donnell, R. M. Gladden, J. E. Zibbell, T. C. Green et al., Characteristics of Fentanyl Overdose -Massachusetts, vol.66, issue.14, pp.382-388, 2014.

E. Chetraru, A. A. Gheddar, L. Raul, J. Kintz, P. Les-«-designer et al., New psychoactive substances -Production, Drugs -Early Warning System -MDMA, PMMA et 25C-NBOMe : Identification de nouveaux comprimés d'ecstasy fortement concentrés en MDMA et en PMMA ainsi que d'un buvard contenant du 25C-NBO. Disponible sur, vol.30, pp.5-18, 2015.

, Décès en relation avec l'abus de médicaments et de substances. Principaux résultats enquête DRAMES, Disponible sur, 2017.

A. Helander and M. Bäckberg, Epidemiology of NPS Based Confirmed Overdose Cases: The STRIDA Project, Handb Exp Pharmacol, vol.252, pp.461-73, 2018.

R. G. Frank and H. A. Pollack, Addressing the Fentanyl Threat to Public Health

, DEA Emerging Threat Reports | NDEWS l National Drug Early Warning System l University of Maryland, Disponible sur

R. Wonguppa and M. Kanato, The prevalence and associated factors of new psychoactive substance use: A 2016 Thailand national household survey, Addict Behav Rep, vol.7, pp.111-116, 2017.

Y. Finkelstein, G. Goel, J. R. Hutson, J. Armstrong, C. R. Baum et al., Drug Misuse in Adolescents Presenting to the Emergency Department, Pediatr Emerg Care. juill, vol.33, issue.7, pp.451-457, 2017.

J. J. Palamar, A. Salomone, E. Gerace, D. Corcia, D. Vincenti et al., Hair testing to assess both known and unknown use of drugs amongst ecstasy users in the electronic dance music scene, Int J Drug Policy, vol.48, pp.91-99, 2017.

C. Kyriakou, M. Pellegrini, O. García-algar, E. Marinelli, and S. Zaami, Recent Trends in Analytical Methods to Determine New Psychoactive Substances in Hair, Curr Neuropharmacol, vol.15, issue.5, pp.663-81, 2017.

E. L. Øiestad, Å. Øiestad, A. Gjelstad, and R. Karinen, Oral fluid drug analysis in the age of new psychoactive substances, Bioanalysis. avr, vol.8, issue.7, pp.691-710, 2016.

S. Strano-rossi, E. Castrignanò, L. Anzillotti, G. Serpelloni, R. Mollica et al., Evaluation of four oral fluid devices (DDS®, Drugtest 5000®, Drugwipe 5+® and RapidSTAT®) for on-site monitoring drugged driving in comparison with UHPLC-MS/MS analysis, Forensic Sci Int, vol.221, issue.1-3, pp.70-76, 2012.

K. G. Shanks, C. W. Benick, and G. , Death Associated With the Use of the Synthetic Cannabinoid ADB-FUBINACA, J Anal Toxicol, vol.40, issue.3, pp.236-245, 2016.

G. R. Brown, . Mclaughlin, and K. Vaughn, Two cases of disseminated intravascular coagulation due to « bath salts » resulting in fatalities, with laboratory confirmation, JAAPA, vol.31, issue.8, pp.1-5, 2018.

D. Sur,

P. Mas-morey, M. Visser, L. Winkelmolen, and D. J. Touw, Clinical Toxicology and Management of Intoxications With Synthetic Cathinones, DEA Issues Carfentanil Warning To Police And Public. Disponible sur, vol.26, issue.4, pp.353-360, 2013.

N. Misailidi, I. Papoutsis, P. Nikolaou, A. Dona, C. Spiliopoulou et al.,

, Fentanyls continue to replace heroin in the drug arena: the cases of ocfentanil and carfentanil, Forensic Toxicol, vol.36, issue.1, pp.12-32, 2018.

J. B. Cole and L. S. Nelson, Controversies and carfentanil: We have much to learn about the present state of opioid poisoning, Am J Emerg Med, vol.35, issue.11, pp.1743-1748, 2017.

P. Krieter, S. Gyaw, R. Crystal, and P. Skolnick, Fighting fire with fire: development of intranasal nalmefene to treat synthetic opioid overdose, J Pharmacol Exp Ther. 2 avr, 2019.

K. Bohnenberger and M. T. Liu, Flubromazolam overdose: A review of a new designer benzodiazepine and the role of flumazenil, Ment Health Clin. 10 mai, vol.9, issue.3, 2019.

, Recommendations for Tox Analysis of NPS Deaths in France

L. E. Kunst and W. A. Gebhardt, Prevalence and Psychosocial Correlates of Party-Drug Use and Associated Problems among University Students in the Netherlands, Subst Use Misuse, vol.15, issue.12, pp.2077-88, 2018.

N. Allibe, C. Richeval, M. Phanithavong, A. Faure, D. Allorge et al., Fatality involving ocfentanil documented by identification of metabolites, Drug Test Anal. juin, vol.10, issue.6, pp.995-1000, 2018.

N. Allibe, C. Richeval, T. Willeman, L. Humbert, D. Allorge et al., Case reports: Four concomitant non-fatal intoxications with AB-FUBINACA and MDMA, Toxicol Anal Clin. févr, vol.29, issue.1, pp.101-111, 2017.

H. Eysseric, N. Allibe, F. Sam-laï, N. Bartoli, M. Bruyère et al.,

U. Norcarfentanil and . Métabolite, Toxicol Anal Clin. juin, vol.30, issue.2, pp.48-57, 2018.

. Eysseric, Opioid toxidrome after cocaine sniffing: first case in Europe of nonfatal overdose by carfentanil laced cocaine. Communication congrès TIAFT présenté à, 2018.

P. Robach, G. Trebes, F. Lasne, C. Buisson, N. Méchin et al., Drug Use on

M. Blanc, A Study Using Automated Urine Collection. Eller K, éditeur, PLOS ONE. 2 juin, vol.11, issue.6, p.156786, 2016.

, Recommandations de la SFTA pour la réalisation des analyses toxicologiques dans les cas de décès impliquant des NPS -version 2019 -SFTA. Disponible sur